Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 0.79 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29926978 | 1.00 | ERBB2 (1.00) | ERBB2EGFRJAK3ERBB4 | |
| SCHEMBL19181012 | 1.00 | ERBB2 (1.00) | ERBB2EGFRJAK3ERBB4 | |
| SCHEMBL19181013 | 1.00 | ERBB2 (1.00) | ERBB2EGFRJAK3ERBB4 | |
| SCHEMBL19180965 | 0.96 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19180964 | 0.96 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19181605 | 0.94 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL31409138 | 0.94 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19182285 | 0.94 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL19182284 | 0.94 | ERBB2 (1.00) | ERBB2EGFR | |
| SCHEMBL31409145 | 0.94 | ERBB2 (1.00) | ERBB2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118987015-A | Application of antisense oligonucleotide in preparation of medicine for treating breast cancer | 北京悦康科创医药科技股份有限公司 | 2024-11-22 | — | — | CN | claimed |
| US-20240336979-A1 | METHODS OF ANALYSIS OF 17Q22 POLYMORPHISMS ASSOCIATED WITH CANCER AND USES THEREOF | UNIVERSIDADE DO ALGARVE (PT) | 2024-10-10 | — | — | US | claimed |
| WO-2024011307-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 AND TREATMENT OF CANCER | THRYV THERAPEUTICS INC. (CA) | 2024-01-18 | — | — | WO | claimed |
| US-20230016003-A1 | SINGLE CELL PATHOLOGY ANALYSIS OF TUMOUR SAMPLES | Universität Zürich (CH) | 2023-01-19 | — | — | US | claimed |
| EP-4090970-A1 | SINGLE CELL PATHOLOGY ANALYSIS OF TUMOUR SAMPLES | Universität Zürich (CH) | 2022-11-23 | — | — | EP | claimed |
| CN-115066609-A | Single cell pathology analysis of tumor samples | 苏黎世大学 | 2022-09-16 | — | — | CN | claimed |
| WO-2026044398-A1 | SALTS OF 5-CHLORO-2-FLUORO-N-(2-FLUORO-4-(3-METHYL-4-[(1-METHYLPIPERIDIN-4-YL)OXY]-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL)PHENYL)BENZENE SULFONAMIDE AND CRYSTALLINE FORMS THEREOF | THRYV THERAPEUTICS INC. (CA) | 2026-03-05 | — | — | WO | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-4578457-A1 | PHARMACEUTICAL FOR TREATING AND/OR PREVENTING CANCER | Toray Industries, Inc. (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20250186400-A1 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | LOXO ONCOLOGY, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12268666-B2 | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | LOXO ONCOLOGY, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| CN-119768182-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2025-04-04 | — | — | CN | disclosed |
| EP-4090970-A1 | SINGLE CELL PATHOLOGY ANALYSIS OF TUMOUR SAMPLES | Universität Zürich (CH) | 2022-11-23 | — | — | EP | disclosed |
| CN-113336760-B | Substituted amide derivatives, compositions and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115066609-A | Single cell pathology analysis of tumor samples | 苏黎世大学 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021232015-A9 | PLATELET DERIVED EXTRACELLULAR VESICLES | CELLPHIRE, INC. (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-114736207-A | Preparation process of small molecule HER2 inhibitor | 武汉九州钰民医药科技有限公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2022076304-A1 | POTENT AND SELECTIVE INHIBITORS OF HER2 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | ARRAY BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186400-A1 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | API5, IL5, SRMS | ERBB2 3304/4885EGFR 3983/4885JAK3 152/4885 |
| US-12268666-B2 | Spray-dried dispersions, formulations, and polymorphs of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | API5, IL5, SRMS | ERBB2 3304/4885EGFR 3983/4885JAK3 152/4885 |
| US-20220081438-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES | FGFR1, FGFR4, FGFR3 | ERBB2 14/4885EGFR 81/4885JAK3 25/4885 |
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | ERBB2 8/4885EGFR 34/4885JAK3 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.